Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 10/2007

01-10-2007 | Research Articles

Can the clinical outcome in state II colon carcinomas be predicted by determination of molecular marker expression?

Authors: J. M. Fernández-Cebrián, M. Nevado Santos, P. Vorwald Kuborn, M. Pardo de Lama, J. Martín-Cavanna, P. Pacheco Martínez, B. Fernández Escudero, M. Ramos Fernández

Published in: Clinical and Translational Oncology | Issue 10/2007

Login to get access
Metadata
Title
Can the clinical outcome in state II colon carcinomas be predicted by determination of molecular marker expression?
Authors
J. M. Fernández-Cebrián
M. Nevado Santos
P. Vorwald Kuborn
M. Pardo de Lama
J. Martín-Cavanna
P. Pacheco Martínez
B. Fernández Escudero
M. Ramos Fernández
Publication date
01-10-2007
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 10/2007
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-007-0119-z

Other articles of this Issue 10/2007

Clinical and Translational Oncology 10/2007 Go to the issue

Case Reports

Glucagonoma with two pancreatic masses and pulmonary metastases as debut of MEN-1

Educational Series

Molecular biology of myeloma

Review

Impact of erythropoietin treatment on the quality of life of oncologic patients

Educational Series

Signalling pathways involved in clinical responses to chemotherapy

Special Article

Treatment of peritoneal carcinomatosis from ovarian cancer. Present, future directions and proposals

Research Articles

Sorafenib TARGET Trial results in Spanish patients
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits